Gastroenterology News

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses data he presented at the GUILD Conference, which show patients with inflammatory bowel disease are at increased risk for cardiovascular events, likely driven by inflammation.

A 12-point plan from the AGA proposed ways in which collaboration between the health care community, insurers, pharmaceutical companies and legislators can improve “fixable problems” affecting patients with inflammatory bowel disease.

Screening patients with psoriasis, uveitis or inflammatory bowel disease for spondyloarthritis could improve early diagnosis, but no existing screening tools are generalizable to all who are at risk, according to a scoping review.

Researchers have estimated that annual costs associated with alcohol-associated liver disease will climb from $31 billion in 2022 to $66 billion in 2040 — a 118% increase — with costs among women accounting for 43% of the total expenditure.

A “vast majority” of liver transplant centers use stigmatizing language, such as “alcoholic” or “alcohol abuse,” when describing patients with alcohol use disorder and alcohol-associated liver disease on their websites, researchers reported.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.

In a Healio video exclusive, Gil Y. Melmed, MD, MS, highlights certain therapies that should be avoided or included in the management of patients with extraintestinal manifestations of inflammatory bowel disease.

High-risk gastrointestinal cancer diagnoses declined sharply during the first 3 months of the COVID-19 pandemic in 2020, but they returned to previous levels by the middle of the year, according to results published in JAMA Network Open.

A new ACG guideline published in The American Journal of Gastroenterology underscored that early management “is essential” to prevent complications such as organ failure and pancreatic necrosis in patients with acute pancreatitis.

Resmetirom 80 mg and 100 mg outperformed placebo in disease resolution and improvement in liver fibrosis among patients with metabolic dysfunction-associated steatohepatitis, according to 52-week results from the MAESTRO-NASH trial.